Profile data is unavailable for this security.
About the company
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
- Revenue in USD (TTM)15.84m
- Net income in USD-308.48m
- Incorporated2012
- Employees480.00
- LocationUniqure NVPaasheuvelweg 25aAMSTERDAM 1105 BPNetherlandsNLD
- Phone+31 202406000
- Fax+31 202406020
- Websitehttp://www.uniqure.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prelude Therapeutics Inc | 0.00 | -121.83m | 212.03m | 128.00 | -- | 0.894 | -- | -- | -2.05 | -2.05 | 0.00 | 4.32 | 0.00 | -- | -- | 0.00 | -48.91 | -47.21 | -53.60 | -51.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| Renovaro Inc | 0.00 | -41.23m | 215.50m | 12.00 | -- | 2.33 | -- | -- | -0.685 | -0.685 | 0.00 | 0.6431 | 0.00 | -- | -- | 0.00 | -59.63 | -27.81 | -72.82 | -28.44 | -- | -- | -- | -- | -- | -22.12 | 0.1299 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
| Omeros Corp | 0.00 | -174.92m | 216.13m | 198.00 | -- | -- | -- | -- | -2.79 | -1.88 | 0.00 | -0.4087 | 0.00 | -- | -- | 0.00 | -36.09 | -55.51 | -44.88 | -70.10 | -- | -- | -- | -- | -- | -5.33 | 1.08 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
| Adverum Biotechnologies Inc | 3.60m | -117.17m | 216.47m | 121.00 | -- | 1.27 | -- | 60.13 | -11.62 | -11.62 | 0.3571 | 8.23 | 0.015 | -- | -- | 29,752.07 | -48.68 | -36.39 | -55.24 | -39.04 | -- | -- | -3,254.58 | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Ovid Therapeutics Inc | 391.69k | -52.34m | 216.68m | 40.00 | -- | 2.46 | -- | 553.19 | -0.7415 | -0.7415 | 0.0056 | 1.24 | 0.0026 | -- | -- | 9,792.25 | -34.98 | -20.78 | -37.27 | -23.27 | -- | -- | -13,362.34 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| Merrimack Pharmaceuticals Inc | 0.00 | -1.18m | 217.98m | -- | -- | 11.48 | -- | -- | -0.0826 | -0.0826 | 0.00 | 1.31 | 0.00 | -- | -- | -- | -6.05 | -23.52 | -6.22 | -26.08 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.51 | -- | -- | -- |
| Conduit Pharmaceuticals Inc | -100.00bn | -100.00bn | 221.49m | -- | -- | -- | -- | -- | -- | -- | -- | -0.0149 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Uniqure NV | 15.84m | -308.48m | 224.36m | 480.00 | -- | 1.08 | -- | 14.16 | -6.47 | -6.47 | 0.3324 | 4.34 | 0.0206 | 1.44 | 0.2973 | 33,006.25 | -40.15 | -12.43 | -44.48 | -13.46 | 13.98 | -- | -1,947.09 | -51.35 | 8.68 | -11.94 | 0.7049 | -- | -85.12 | 7.02 | -143.30 | -- | 11.00 | -- |
| AVITA Medical Inc | 50.14m | -35.38m | 225.75m | 207.00 | -- | 4.58 | -- | 4.50 | -1.40 | -1.40 | 1.98 | 1.91 | 0.4778 | 1.96 | 8.48 | 242,236.70 | -33.71 | -- | -38.04 | -- | 84.93 | -- | -70.56 | -- | 7.46 | -35.33 | 0.448 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
| INmune Bio Inc | 155.00k | -30.01m | 228.63m | 11.00 | -- | 5.45 | -- | 1,475.06 | -1.67 | -1.67 | 0.0086 | 2.12 | 0.0022 | -- | 0.0284 | 14,090.91 | -43.24 | -37.82 | -54.85 | -41.86 | -- | -- | -19,360.00 | -14,901.03 | -- | -13.06 | 0.2064 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| Compass Therapeutics Inc. | 0.00 | -42.49m | 233.90m | 32.00 | -- | 1.46 | -- | -- | -0.3343 | -0.3343 | 0.00 | 1.16 | 0.00 | -- | -- | 0.00 | -23.84 | -41.75 | -25.56 | -46.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
| Puma Biotechnology Inc | 235.64m | 21.59m | 234.44m | 185.00 | 10.76 | 4.33 | 7.08 | 0.9949 | 0.4515 | 0.4515 | 4.96 | 1.12 | 1.04 | 10.80 | 5.23 | 1,273,714.00 | 9.54 | -12.21 | 15.66 | -20.53 | 73.40 | 78.78 | 9.16 | -11.79 | 1.50 | 3.10 | 0.6509 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
| G1 Therapeutics Inc | 84.04m | -30.59m | 234.74m | 100.00 | -- | 8.45 | -- | 2.79 | -0.6146 | -0.6146 | 1.55 | 0.531 | 0.6367 | 0.4852 | 6.07 | 840,410.00 | -23.18 | -47.06 | -30.95 | -52.64 | 91.89 | -- | -36.40 | -268.59 | 2.55 | -3.31 | 0.6084 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
| Metagenomi Inc | 44.76m | -68.26m | 236.83m | 236.00 | -- | -- | -- | 5.29 | -1.82 | -1.82 | 1.19 | 5.73 | -- | -- | -- | 189,644.10 | -- | -- | -- | -- | -- | -- | -152.50 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| AC Immune SA | 16.35m | -59.90m | 237.08m | 133.00 | -- | 1.34 | -- | 14.50 | -0.7089 | -0.7089 | 0.1925 | 1.79 | 0.0803 | -- | 1.92 | 122,913.30 | -29.41 | -18.25 | -31.56 | -19.52 | -- | -- | -366.41 | -148.29 | -- | -89.52 | 0.0213 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
Data as of May 03 2024. Currency figures normalised to Uniqure NV's reporting currency: US Dollar USD
41.81%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Vestal Point Capital LPas of 31 Dec 2023 | 3.93m | 8.21% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 3.48m | 7.27% |
| Nantahala Capital Management LLCas of 31 Dec 2023 | 2.96m | 6.18% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 1.73m | 3.62% |
| 683 Capital Management LLCas of 31 Dec 2023 | 1.69m | 3.54% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 1.46m | 3.06% |
| Pictet Asset Management SAas of 31 Dec 2023 | 1.32m | 2.77% |
| SV Health Managers LLPas of 30 Sep 2023 | 1.24m | 2.60% |
| Schroder Investment Management Ltd.as of 31 Dec 2023 | 1.24m | 2.60% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 947.00k | 1.98% |
More ▼
Data from 30 Sep 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
